Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed its FY2025 consolidated revenue forecast of KRW 5.5705T (midpoint of the expected YoY growth range of +20% to +25%). The variance between the FY2024 revenue forecast and actual performance was 4.7%. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key…

Read More “[Disclosure] Samsung Biologics (207940) – Outlook on Operating Results Based on Consolidated Financial Statements (Fair Disclosure) / 2025-01-22” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen reiterated that while a potential issuance of KRW 200.00B in Redeemable Convertible Preferred Shares (RCPS) is under consideration, nothing has been concretely finalized, and no lead manager agreement has been signed with Shinhan Securities. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key…

Read More “[Disclosure] ALTEOGEN (196170) – Clarification on Rumors or News Reports (Unconfirmed) / 2025-01-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen received a final decision of non-designation as an unfaithful disclosure corporation as mitigating factors were accepted following prior notices regarding two disclosure reversals (cancellation of subsidiary merger and stock acquisition). 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Finalization…

Read More “[Disclosure] ALTEOGEN (196170) – Non-Designation as Unfaithful Disclosure Corporation (2 Cases of Disclosure Reversal) / 2025-01-15” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion submitted a Phase 3 Clinical Trial Application (CTA) to the Ministry of Food and Drug Safety (MFDS) of South Korea for CT-P51, a biosimilar candidate referencing Keytruda, targeting patients with metastatic non-squamous non-small cell lung cancer. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s…

Read More “[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Korea / 2025-01-15” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company valued at approx. KRW 2.0747T (USD 1,410,110,000), representing 56.15% of its FY2023 consolidated revenue. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring…

Read More “[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract / 2025-01-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is executing a modified listing on January 16, 2025, to reflect the cancellation of 3,011,910 common shares, reducing its total issued shares. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Share Count Adjustment Following Modified Listing…

Read More “[Disclosure] Celltrion (068270) – (Correction) Change of Listing (Share Cancellation) / 2025-01-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is executing a modified listing on January 16, 2025, to reflect the cancellation of 3,011,910 common shares, reducing its total issued shares. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Share Count Adjustment Following Modified Listing…

Read More “[Disclosure] Celltrion (068270) – Change of Listing (Share Cancellation) / 2025-01-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an advance notice disclosing that it plans to announce its FY2024 financial results (covering Jan 1, 2024 – Dec 31, 2024) on January 22, 2025. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Earnings Release…

Read More “[Disclosure] Samsung Biologics (207940) – Advance Notice of Financial Results Announcement / 2025-01-08” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received Phase 3 Clinical Trial Application (IND) approval from the US Food and Drug Administration (FDA) for CT-P44, a biosimilar candidate referencing Darzalex. 약업신문 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Clinical Trial Progress and Patient Recruitment…

Read More “[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in the US / 2024-12-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to acquire 546,747 treasury common shares worth approximately KRW 100.0B through on-market purchases to stabilize its stock price and enhance shareholder value. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Execution of On-Market Purchases and Completion of Acquisition…

Read More “[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2024-12-27” »